Pro-apoptotic role of NF-κB: Implications for cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1766, Issue 1, 2006, Pages 53-62

  Radhakrishnan, Senthil K ^a   Kamalakaran, Sitharthan ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Apoptosis; Cancer; Drug target; NF B

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; DAUNORUBICIN; DEATH RECEPTOR 5; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; PROTEIN P100; RETINOID; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CARCINOGENICITY; CELL CYCLE ARREST; CELL DEATH; CELL TYPE; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; GENE IDENTIFICATION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; LUNG CANCER; MELANOMA; MOLECULAR MECHANICS; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVIEW; RNA INTERFERENCE; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; APOPTOSIS; HUMANS; NEOPLASMS; NF-KAPPA B;

EID: 33746829168     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2006.02.001     Document Type: Review

References (110)

1. Chen L.F., and Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev., Mol. Cell Biol. 5 (2004) 392-401
2. Dechend R., Hirano F., Lehmann K., Heissmeyer V., Ansieau S., Wulczyn F.G., Scheidereit C., and Leutz A. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 18 (1999) 3316-3323
3. Wessells J., Baer M., Young H.A., Claudio E., Brown K., Siebenlist U., and Johnson P.F. BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J. Biol. Chem. 279 (2004) 49995-50003
4. Motoyama M., Yamazaki S., Eto-Kimura A., Takeshige K., and Muta T. Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein. J. Biol. Chem. 280 (2005) 7444-7451
5. Shen J., Channavajhala P., Seldin D.C., and Sonenshein G.E. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. J. Immunol. 167 (2001) 4919-4925
6. Kato Jr. T., Delhase M., Hoffmann A., and Karin M. CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol. Cell 12 (2003) 829-839
7. Miyamoto S., Seufzer B.J., and Shumway S.D. Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells. Mol. Cell. Biol. 18 (1998) 19-29
8. Schwarz E.M., Van Antwerp D., and Verma I.M. Constitutive phosphorylation of IkappaBalpha by casein kinase II occurs preferentially at serine 293: requirement for degradation of free IkappaBalpha. Mol. Cell. Biol. 16 (1996) 3554-3559
9. Mercurio F., DiDonato J.A., Rosette C., and Karin M. p105 and p98 precursor proteins play an active role in NF-kappa B-mediated signal transduction. Genes Dev. 7 (1993) 705-718
10. Li Z.W., Chu W., Hu Y., Delhase M., Deerinck T., Ellisman M., Johnson R., and Karin M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J. Exp. Med. 189 (1999) 1839-1845
11. Tanaka M., Fuentes M.E., Yamaguchi K., Durnin M.H., Dalrymple S.A., Hardy K.L., and Goeddel D.V. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 10 (1999) 421-429
12. Luedde T., Assmus U., Wustefeld T., Meyer zu Vilsendorf A., Roskams T., Schmidt-Supprian M., Rajewsky K., Brenner D.A., Manns M.P., Pasparakis M., and Trautwein C. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J. Clin. Invest. 115 (2005) 849-859
13. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 (2002) S81-S96 (Suppl.)
14. Kucharczak J., Simmons M.J., Fan Y., and Gelinas C. To be, or not to be: NF-kappaB is the answer-Role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22 (2003) 8961-8982
15. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
16. Duyao M.P., Kessler D.J., Spicer D.B., Bartholomew C., Cleveland J.L., Siekevitz M., and Sonenshein G.E. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J. Biol. Chem. 267 (1992) 16288-16291
17. Toth C.R., Hostutler R.F., Baldwin Jr. A.S., and Bender T.P. Members of the nuclear factor kappa B family transactivate the murine c-myb gene. J. Biol. Chem. 270 (1995) 7661-7671
18. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Baldwin Jr. A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19 (1999) 5785-5799
19. Hinz M., Krappmann D., Eichten A., Heder A., Scheidereit C., and Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19 (1999) 2690-2698
20. Duyao M.P., Kessler D.J., Spicer D.B., and Sonenshein G.E. Transactivation of the c-myc gene by HTLV-1 tax is mediated by NFkB. Curr. Top. Microbiol. Immunol. 182 (1992) 421-424
21. Mayo M.W., Norris J.L., and Baldwin A.S. Ras regulation of NF-kappa B and apoptosis. Methods Enzymol. 333 (2001) 73-87
22. Kim B.Y., Gaynor R.B., Song K., Dritschilo A., and Jung M. Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells. Oncogene 21 (2002) 4490-4497
23. Fox C.J., Hammerman P.S., Cinalli R.M., Master S.R., Chodosh L.A., and Thompson C.B. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17 (2003) 1841-1854
24. Hammerman P.S., Fox C.J., Cinalli R.M., Xu A., Wagner J.D., Lindsten T., and Thompson C.B. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res. 64 (2004) 8341-8348
25. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
26. Pauletti G., Dandekar S., Rong H., Ramos L., Peng H., Seshadri R., and Slamon D.J. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 18 (2000) 3651-3664
27. Zhou B.P., Hu M.C.-T., Miller S.A., Yu Z., Xia W., Lin S.-Y., and Hung M.-C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappa B pathway. J. Biol. Chem. 275 (2000) 8027-8031
28. Takeshita H., Yoshizaki T., Miller W.E., Sato H., Furukawa M., Pagano J.S., and Raab-Traub N. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J. Virol. 73 (1999) 5548-5555
29. Bond M., Fabunmi R.P., Baker A.H., and Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 435 (1998) 29-34
30. van de Stolpe A., Caldenhoven E., Stade B.G., Koenderman L., Raaijmakers J.A., Johnson J.P., and van der Saag P.T. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J. Biol. Chem. 269 (1994) 6185-6192
31. Shishodia S., and Aggarwal B.B. Nuclear factor-kappaB: a friend or a foe in cancer?. Biochem. Pharmacol. 68 (2004) 1071-1080
32. Adams V., Nehrhoff B., Spate U., Linke A., Schulze P.C., Baur A., Gielen S., Hambrecht R., and Schuler G. Induction of iNOS expression in skeletal muscle by IL-1beta and NFkappaB activation: an in vitro and in vivo study. Cardiovasc. Res. 54 (2002) 95-104
33. Tschugguel W., Pustelnik T., Lass H., Mildner M., Weninger W., Schneeberger C., Jansen B., Tschachler E., Waldhor T., Huber J.C., and Pehamberger H. Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. Br. J. Cancer 79 (1999) 1609-1612
34. Helbig G., Christopherson II K.W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D., Broxmeyer H.E., and Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278 (2003) 21631-21638
35. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107 (2001) 241-246
36. Janssens S., and Tschopp J. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. (2006)
37. Janssens S., Tinel A., Lippens S., and Tschopp J. PIDD mediates NF-kappaB activation in response to DNA damage. Cell 123 (2005) 1079-1092
38. Garg A., and Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16 (2002) 1053-1068
39. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev., Drug Discov. 3 (2004) 17-26
40. Nakanishi C., and Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev., Cancer 5 (2005) 297-309
41. Cusack Jr. J.C., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., and Baldwin Jr. A.S. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61 (2001) 3535-3540
42. Ryan K.M., Ernst M.K., Rice N.R., and Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404 (2000) 892-897
43. Bohuslav J., L.-f. Chen H., Kwon Y., and Mu W.C. p53 induces NF-{kappa}B activation by an I{kappa}B kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 279 (2004) 26115-26125
44. Webster G.A., and Perkins N.D. Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19 (1999) 3485-3495
45. Kashatus D., Cogswell P., and Baldwin A.S. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 20 (2006) 225-235
46. Tergaonkar V., Pando M., Vafa O., Wahl G., and Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1 (2002) 493-503
47. Ricca A., Biroccio A., Trisciuoglio D., Cippitelli M., Zupi G., and Del Bufalo D. relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. Br. J. Cancer 85 (2001) 1914-1921
48. Sheehy A.M., and Schlissel M.S. Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line. J. Biol. Chem. 274 (1999) 8708-8716
49. Kaltschmidt B., Kaltschmidt C., Hofmann T.G., Hehner S.P., Droge W., and Schmitz M.L. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur. J. Biochem. 267 (2000) 3828-3835
50. Kaltschmidt B., Heinrich M., and Kaltschmidt C. Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells. Neuromol. Med. 2 (2002) 299-309
51. Tarabin V., and Schwaninger M. The role of NF-kappaB in 6-hydroxydopamine- and TNFalpha-induced apoptosis of PC12 cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 563-569
52. Lin B., Williams-Skipp C., Tao Y., Schleicher M.S., Cano L.L., Duke R.C., and Scheinman R.I. NF-kappaB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type. Cell Death Differ. 6 (1999) 570-582
53. Bernard D., Monte D., Vandenbunder B., and Abbadie C. The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD. Oncogene 21 (2002) 4392-4402
54. Shetty S., Gladden J.B., Henson E.S., Hu X., Villanueva J., Haney N., and Gibson S.B. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 7 (2002) 413-420
55. Shetty S., Graham B.A., Brown J.G., Hu X., Vegh-Yarema N., Harding G., Paul J.T., and Gibson S.B. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell. Biol. 25 (2005) 5404-5416
56. Ravi R., Bedi G.C., Engstrom L.W., Zeng Q., Mookerjee B., Gelinas C., Fuchs E.J., and Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3 (2001) 409-416
57. Kumari A.L., Ali A.M., Das S., Pardhasaradhi B.V., Varalakshmi C., and Khar A. Role of STAT3 and NFkappaB signaling in the serum factor-induced apoptosis in AK-5 cells. Biochem. Biophys. Res. Commun. 336 (2005) 860-867
58. Rivera-Walsh I., Waterfield M., Xiao G., Fong A., and Sun S.-C. NF-kappa B signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I tax-induced T-cell death. J. Biol. Chem. 276 (2001) 40385-40388
59. Jin F., Liu X., Zhou Z., Yue P., Lotan R., Khuri F.R., Chung L.W., and Sun S.Y. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res. 65 (2005) 6354-6363
60. Farhana L., Dawson M.I., and Fontana J.A. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res. 65 (2005) 4909-4917
61. Kuhnel F., Zender L., Paul Y., Tietze M.K., Trautwein C., Manns M., and Kubicka S. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275 (2000) 6421-6427
62. Kimura M., Haisa M., Uetsuka H., Takaoka M., Ohkawa T., Kawashima R., Yamatsuji T., Gunduz M., Kaneda Y., Tanaka N., and Naomoto Y. TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ. 10 (2003) 718-728
63. Ouaaz F., Li M., and Beg A.A. A critical role for the RelA subunit of nuclear factor kappaB in regulation of multiple immune-response genes and in Fas-induced cell death. J. Exp. Med. 189 (1999) 999-1004
64. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., and Green D.R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol. Cell 1 (1998) 543-551
65. Harwood F.G., Kasibhatla S., Petak I., Vernes R., Green D.R., and Houghton J.A. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J. Biol. Chem. 275 (2000) 10023-10029
66. Wu H., and Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J. Biol. Chem. 269 (1994) 20067-20074
67. Benoit V., Hellin A.C., Huygen S., Gielen J., Bours V., and Merville M.P. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter. Oncogene 19 (2000) 4787-4794
68. Kirch H.C., Flaswinkel S., Rumpf H., Brockmann D., and Esche H. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene 18 (1999) 2728-2738
69. Aleyasin H., Cregan S.P., Iyirhiaro G., O'Hare M.J., Callaghan S.M., Slack R.S., and Park D.S. Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage. J. Neurosci. 24 (2004) 2963-2973
70. Shou Y., Li N., Li L., Borowitz J.L., and Isom G.E. NF-kappaB-mediated up-regulation of Bcl-X(S) and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J. Neurochem. 81 (2002) 842-852
71. Kim S.J., Hwang S.G., Shin D.Y., Kang S.S., and Chun J.S. p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J. Biol. Chem. 277 (2002) 33501-33508
72. Qin Z.H., Chen R.W., Wang Y., Nakai M., Chuang D.M., and Chase T.N. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J. Neurosci. 19 (1999) 4023-4033
73. Gartel A.L., and Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65 (2005) 3980-3985
74. Fujioka S., Schmidt C., Sclabas G.M., Li Z., Pelicano H., Peng B., Yao A., Niu J., Zhang W., Evans D.B., Abbruzzese J.L., Huang P., and Chiao P.J. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-{kappa}B. J. Biol. Chem. 279 (2004) 27549-27559
75. Li Z., Niu J., Uwagawa T., Peng B., and Chiao P.J. Function of polo-like kinase 3 in NF-{kappa}B-mediated proapoptotic response. J. Biol. Chem. 280 (2005) 16843-16850
76. Shim M., and Eling T.E. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J. Biol. Chem. 280 (2005) 18636-18642
77. Segev D.L., Ha T.U., Tran T.T., Kenneally M., Harkin P., Jung M., MacLaughlin D.T., Donahoe P.K., and Maheswaran S. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J. Biol. Chem. 275 (2000) 28371-28379
78. Hoshiya Y., Gupta V., Segev D.L., Hoshiya M., Carey J.L., Sasur L.M., Tran T.T., Ha T.U., and Maheswaran S. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol. Cell. Endocrinol. 211 (2003) 43-49
79. Segev D.L., Hoshiya Y., Hoshiya M., Tran T.T., Carey J.L., Stephen A.E., MacLaughlin D.T., Donahoe P.K., and Maheswaran S. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 239-244
80. Segev D.L., Hoshiya Y., Stephen A.E., Hoshiya M., Tran T.T., MacLaughlin D.T., Donahoe P.K., and Maheswaran S. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo. J. Biol. Chem. 276 (2001) 26799-26806
81. Campbell K.J., Rocha S., and Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell 13 (2004) 853-865
82. Rocha S., Campbell K.J., and Perkins N.D. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol. Cell 12 (2003) 15-25
83. Rocha S., Garrett M.D., Campbell K.J., Schumm K., and Perkins N.D. Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 24 (2005) 1157-1169
84. Rocha S., and Perkins N.D. ARF the integrator: linking NF-kappaB, p53 and checkpoint kinases. Cell Cycle 4 (2005) 756-759
85. Campbell K.J., Witty J.M., Rocha S., and Perkins N.D. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-{kappa}B transactivation. Cancer Res. 66 (2006) 929-935
86. Poppelmann B., Klimmek K., Strozyk E., Voss R., Schwarz T., and Kulms D. NF{kappa}B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis. J. Biol. Chem. 280 (2005) 15635-15643
87. Wang Y., Cui H., Schroering A., Ding J.L., Lane W.S., McGill G., Fisher D.E., and Ding H.F. NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat. Cell Biol. 4 (2002) 888-893
88. Feinstein E., Kimchi A., Wallach D., Boldin M., and Varfolomeev E. The death domain: a module shared by proteins with diverse cellular functions. Trends Biochem. Sci. 20 (1995) 342-344
89. Hacker H., and Karin M. Is NF-kappaB2/p100 a direct activator of programmed cell death?. Cancer Cell 2 (2002) 431-433
90. Luo J.-L., Kamata H., and Karin M. IKK/NF-{kappa}B signaling: balancing life and death-A new approach to cancer therapy. J. Clin. Invest. 115 (2005) 2625-2632
91. Ashikawa K., Shishodia S., Fokt I., Priebe W., and Aggarwal B.B. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol. 67 (2004) 353-364
92. Spalding A.C., Jotte R.M., Scheinman R.I., Geraci M.W., Clarke P., Tyler K.L., and Johnson G.L. TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene 21 (2002) 260-271
93. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., and Opipari Jr. A.W. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 276 (2001) 48921-48929
94. Gapuzan M.E., Schmah O., Pollock A.D., Hoffmann A., and Gilmore T.D. Immortalized fibroblasts from NF-kappaB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras. Oncogene 24 (2005) 6574-6583
95. Gapuzan M.E., Yufit P.V., and Gilmore T.D. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappaB have a malignantly transformed phenotype. Oncogene 21 (2002) 2484-2492
96. Campbell K.J., and Perkins N.D. Post-translational modification of RelA(p65) NF-kappaB. Biochem. Soc. Trans. 32 (2004) 1087-1089
97. Quivy V., and Van Lint C. Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem. Pharmacol. 68 (2004) 1221-1229
98. Chen L.F., Mu Y., and Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 21 (2002) 6539-6548
99. Chen L.-F., Williams S.A., Mu Y., Nakano H., Duerr J.M., Buckbinder L., and Greene W.C. NF-{kappa}B RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25 (2005) 7966-7975
100. Anrather J., Racchumi G., and Iadecola C. cis-acting element-specific transcriptional activity of differentially phosphorylated nuclear factor-{kappa}B. J. Biol. Chem. 280 (2005) 244-252
101. Buss H., Dorrie A., Schmitz M.L., Frank R., Livingstone M., Resch K., and Kracht M. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J. Biol. Chem. 279 (2004) 49571-49574
102. Steinbrecher K.A., Wilson III W., Cogswell P.C., and Baldwin A.S. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol. Cell. Biol. 25 (2005) 8444-8455
103. Campbell K.J., and Perkins N.D. Reprogramming RelA. Cell Cycle 3 (2004) 869-872
104. Miyamoto S. RelA life and death decisions. Mol. Cell 13 (2004) 763-764
105. Graham B., and Gibson S.B. The two faces of NFkappaB in cell survival responses. Cell Cycle 4 (2005) 1342-1345
106. Saccani S., Pantano S., and Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol. 3 (2002) 69-75
107. Perkins N.D., and Gilmore T.D. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. (2006) (in press)
108. Perkins N.D. NF-kappaB: tumor promoter or suppressor?. Trends Cell Biol. 14 (2004) 64-69
109. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1 (2002) 639-649
110. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-348